SG11201508911PA - Human fcrn-binding modified antibodies and methods of use - Google Patents

Human fcrn-binding modified antibodies and methods of use

Info

Publication number
SG11201508911PA
SG11201508911PA SG11201508911PA SG11201508911PA SG11201508911PA SG 11201508911P A SG11201508911P A SG 11201508911PA SG 11201508911P A SG11201508911P A SG 11201508911PA SG 11201508911P A SG11201508911P A SG 11201508911PA SG 11201508911P A SG11201508911P A SG 11201508911PA
Authority
SG
Singapore
Prior art keywords
methods
human fcrn
modified antibodies
binding modified
binding
Prior art date
Application number
SG11201508911PA
Inventor
Guido Hartmann
Joerg Thomas Regula
Matthias Rueth
Wolfgang Schaefer
Tilman Schlothauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201508911PA publication Critical patent/SG11201508911PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201508911PA 2013-04-29 2014-04-25 Human fcrn-binding modified antibodies and methods of use SG11201508911PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13165744 2013-04-29
EP14151316 2014-01-15
PCT/EP2014/058417 WO2014177460A1 (en) 2013-04-29 2014-04-25 Human fcrn-binding modified antibodies and methods of use

Publications (1)

Publication Number Publication Date
SG11201508911PA true SG11201508911PA (en) 2015-11-27

Family

ID=50678163

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201800492PA SG10201800492PA (en) 2013-04-29 2014-04-25 Human fcrn-binding modified antibodies and methods of use
SG11201508911PA SG11201508911PA (en) 2013-04-29 2014-04-25 Human fcrn-binding modified antibodies and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201800492PA SG10201800492PA (en) 2013-04-29 2014-04-25 Human fcrn-binding modified antibodies and methods of use

Country Status (23)

Country Link
US (2) US11091541B2 (en)
EP (2) EP3628685A1 (en)
JP (3) JP2016528167A (en)
KR (2) KR102282134B1 (en)
CN (1) CN105143262A (en)
AU (3) AU2014261630B2 (en)
BR (1) BR112015027385A2 (en)
CA (1) CA2904806C (en)
CL (3) CL2015003126A1 (en)
CR (1) CR20150512A (en)
EA (1) EA201501063A1 (en)
ES (1) ES2746136T3 (en)
HK (1) HK1213578A1 (en)
IL (1) IL241787B (en)
MX (1) MX365787B (en)
MY (1) MY172430A (en)
PE (2) PE20190920A1 (en)
PH (1) PH12015502470A1 (en)
PL (1) PL2992012T3 (en)
SG (2) SG10201800492PA (en)
TW (1) TWI747803B (en)
UA (1) UA118029C2 (en)
WO (1) WO2014177460A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CN105164157B (en) * 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Modified asymmetric antibodies to FC-receptor binding and methods of use
KR20160107190A (en) * 2014-01-15 2016-09-13 에프. 호프만-라 로슈 아게 Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015107025A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
JP6778110B2 (en) * 2014-01-15 2020-10-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Fc region variant with improved protein A binding
MX2016014210A (en) 2014-04-30 2017-05-01 Hanall Biopharma Co Ltd Antibody binding to fcrn for treating autoimmune diseases.
US10336825B2 (en) 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
ES2749383T3 (en) 2014-11-06 2020-03-20 Hoffmann La Roche Variants of the Fc Region with Modified FcRn Binding and Methods of Use
KR20170082520A (en) 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 Anti-pdgf-b antibodies and methods of use
CA2963606A1 (en) * 2014-11-10 2016-05-19 F.Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
RU2017120358A (en) 2014-11-10 2018-12-13 Ф.Хоффманн-Ля Рош Аг ANTI-IL-1-BETA ANTIBODIES AND WAYS OF THEIR APPLICATION
SG11201703428SA (en) * 2014-11-10 2017-05-30 Hoffmann La Roche Bispecific antibodies and methods of use in ophthalmology
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
CN108699162A (en) * 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 Novel anti-angiogenesis fused polypeptide
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
AU2017325654A1 (en) 2016-08-02 2019-02-14 Visterra, Inc. Engineered polypeptides and uses thereof
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CA3056837A1 (en) 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptors
JP6871415B2 (en) 2017-04-05 2021-05-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Anti-LAG3 antibody
CN110573626B (en) * 2017-04-28 2024-05-03 豪夫迈·罗氏有限公司 Antibody selection methods
WO2018237037A2 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
JP7074859B2 (en) * 2017-12-22 2022-05-24 エフ．ホフマン－ラ ロシュ アーゲー Method of depletion of light chain mismatched antibody variants by hydrophobic interaction chromatography
JP2021508471A (en) 2017-12-29 2021-03-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ How to Improve VEGF Receptor Blocking Selectivity of Anti-VEGF Antibodies
CN111683961A (en) 2018-03-13 2020-09-18 豪夫迈·罗氏有限公司 Therapeutic combinations of 4-1BB agonists with anti-CD 20 antibodies
TW202003839A (en) 2018-03-29 2020-01-16 美商建南德克公司 Modulating lactogenic activity in mammalian cells
CN112955240B (en) * 2018-10-25 2022-09-16 豪夫迈·罗氏有限公司 Modification of antibody FcRn binding
EP3877416A4 (en) * 2018-10-30 2022-07-27 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof
BR112021012022A2 (en) 2018-12-21 2021-11-03 Hoffmann La Roche Antibody that binds to vegf and il-1beta and methods of use
JP7249432B2 (en) * 2019-03-29 2023-03-30 エフ． ホフマン－ラ ロシュ アーゲー SPR-based binding assays for functional analysis of multivalent molecules
CA3141471A1 (en) * 2019-07-02 2021-01-07 Michael Paul Wheatcroft Antibodies for binding psma with reduced affinity for the neonatal fc receptor
MX2021015670A (en) * 2019-07-02 2022-04-18 Telix Int Pty Ltd Antibodies against caix with reduced affinity for the neonatal fc receptor.
AR119382A1 (en) 2019-07-12 2021-12-15 Hoffmann La Roche PRE-TARGETING ANTIBODIES AND METHODS OF USE
MX2022001433A (en) * 2019-08-06 2022-02-22 Hoffmann La Roche Personalized treatment of ophthalmologic diseases.
CR20220156A (en) 2019-09-18 2022-05-23 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2021055669A1 (en) * 2019-09-20 2021-03-25 Adimab, Llc Fc variants with reduced effector function
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4127153A2 (en) 2020-03-26 2023-02-08 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
WO2021198034A1 (en) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use
CA3176792A1 (en) * 2020-04-29 2021-11-04 Katherine HARRIS Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions
UY39191A (en) * 2020-04-29 2021-11-30 Teneobio Inc MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
KR20230020975A (en) 2020-06-08 2023-02-13 에프. 호프만-라 로슈 아게 Anti-HBV Antibodies and Methods of Use
KR20230026491A (en) 2020-06-24 2023-02-24 제넨테크, 인크. Apoptosis resistant cell lines
EP4178985A1 (en) 2020-07-10 2023-05-17 F. Hoffmann-La Roche AG Antibodies which bind to cancer cells and target radionuclides to said cells
BR112023000839A2 (en) 2020-07-17 2023-02-07 Genentech Inc ISOLATED ANTIBODIES, ISOLATED NUCLEIC ACID, HOST CELL, METHODS FOR PRODUCING AN ANTIBODY THAT BINDS TO HUMAN NOTCH2, FOR TREATING AN INDIVIDUAL WITH A MUCO-OBSTRUCTIVE PULMONARY DISEASE, AND FOR REDUCING THE NUMBER OF SECRETORY CELLS IN AN INDIVIDUAL, PHARMACEUTICAL COMPOSITION, ANTIBODY, ANTIBODY FOR USE AND USE OF THE ANTIBODY
CN116648507A (en) 2020-08-28 2023-08-25 基因泰克公司 CRISPR/Cas9 multiple knockout of host cell proteins
KR20230061458A (en) 2020-09-04 2023-05-08 에프. 호프만-라 로슈 아게 Antibodies that bind to VEGF-A and ANG2 and methods of use
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
KR20230131204A (en) 2021-01-12 2023-09-12 에프. 호프만-라 로슈 아게 Fractionated antibodies that bind to cancer cells and target radionuclides to those cells
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
JP2024509695A (en) 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド Multispecific binding proteolysis platform and methods of use
EP4304732A1 (en) 2021-03-12 2024-01-17 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
TW202305122A (en) 2021-04-19 2023-02-01 美商建南德克公司 Modified mammalian cells
EP4341385A1 (en) 2021-05-21 2024-03-27 Genentech, Inc. Modified cells for the production of a recombinant product of interest
EP4370545A1 (en) 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
AU2022310847A1 (en) 2021-07-14 2024-01-25 Genentech, Inc. Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
WO2023012147A1 (en) 2021-08-03 2023-02-09 F. Hoffmann-La Roche Ag Bispecific antibodies and methods of use
WO2023094282A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Quantification of low amounts of antibody sideproducts
CA3237618A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
TW202340251A (en) 2022-01-19 2023-10-16 美商建南德克公司 Anti-notch2 antibodies and conjugates and methods of use
TW202402810A (en) 2022-05-11 2024-01-16 瑞士商赫孚孟拉羅股份公司 Antibody that binds to vegf-a and il6 and methods of use
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability
WO2023235679A1 (en) * 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
WO2024020564A1 (en) 2022-07-22 2024-01-25 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
WO2024077239A1 (en) 2022-10-07 2024-04-11 Genentech, Inc. Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech Inc METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
SI1325932T1 (en) 1997-04-07 2005-08-31 Genentech Inc
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (en) 1997-06-24 2005-12-01 Genentech, Inc. PROCEDURE AND COMPOSITIONS OF GALACTOSILATED GLICOPROTEINS.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (en) 1997-10-31 2009-02-12 Genentech Inc METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (en) 1998-04-02 2007-10-15 Genentech Inc ANTIBODIES VARIANTS AND FRAGMENTS THEREOF
ES2434961T5 (en) 1998-04-20 2018-01-18 Roche Glycart Ag Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
BR0008758A (en) 1999-01-15 2001-12-04 Genentech Inc Variants of parental polypeptides with altered effector function, polypeptides, isolated nucleic acid composition, vector, host cell, method for producing a polypeptide variant, method for treating a disorder in mammals and method for producing a variant fc region
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (en) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedure to control the activity of an immunofunctional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT1222292E (en) 1999-10-04 2005-11-30 Medicago Inc METHOD FOR REGULATING THE TRANSCRIPTION OF EXOGENEOUS GENES IN THE PRESENCE OF NITROGEN
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
IL149809A0 (en) 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
MXPA02010011A (en) 2000-04-11 2003-04-25 Genentech Inc Multivalent antibodies and uses therefor.
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE378403T1 (en) 2000-11-30 2007-11-15 Medarex Inc TRANSCHROMOSOMAL TRANSGENIC RODENTS FOR PRODUCING HUMAN ANTIBODIES
WO2004058821A2 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DE60237282D1 (en) 2001-06-28 2010-09-23 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND ITS USE
KR100988949B1 (en) 2001-10-25 2010-10-20 제넨테크, 인크. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1490677A4 (en) 2002-02-27 2006-01-18 California Inst Of Techn Computational method for designing enzymes for incorporation of amino acid analogs into proteins
JPWO2003085118A1 (en) 2002-04-09 2005-08-11 協和醗酵工業株式会社 Method for producing antibody composition
CN1930288B (en) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 Cells of which genome is modified
JP4832719B2 (en) 2002-04-09 2011-12-07 協和発酵キリン株式会社 Medicine containing antibody composition for FcγRIIIa polymorphism patients
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AR046071A1 (en) 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
DK1656391T3 (en) 2003-08-13 2011-01-03 Pfizer Prod Inc Modified human IGF-1R antibodies
JP2007507237A (en) 2003-10-03 2007-03-29 ユニバーシティー オブ フロリダ リサーチ ファウンデイション インコーポレイテッド Materials and methods for the synthesis of flavor and aromatic volatiles in plants
WO2005035586A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
ES2737837T3 (en) 2003-10-09 2020-01-16 Ambrx Inc Polymeric derivatives
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
EA025962B1 (en) 2003-11-05 2017-02-28 Роше Гликарт Аг ANTIBODIES HAVING INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
MXPA06008507A (en) 2004-02-02 2008-02-13 Ambrx Inc Modified human four helical bundle polypeptides and their uses.
ZA200608130B (en) 2004-03-31 2008-12-31 Genentech Inc Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
BR122019012028B1 (en) 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag ANTI-P-SELECTIN ANTIBODIES, NUCLEIC ACID MOLECULE, VECTOR, AND COMPOSITION
JP2008510466A (en) 2004-08-19 2008-04-10 ジェネンテック・インコーポレーテッド Polypeptide variants with altered effector function
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
ES2669510T3 (en) 2004-09-23 2018-05-28 Genentech, Inc. Antibodies and conjugates engineered with cysteine
US20080070675A1 (en) 2004-10-01 2008-03-20 Gagner Mark B Method and Apparatus for Serverless Storage of Information
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ES2320374T3 (en) 2005-01-05 2009-05-21 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. DOMAINS OF SYNTHETIC IMMUNOGLOBULIN WITH MODIFIED LINK PROPERTIES IN MOLECULA REGIONS DIFFERENT FROM COMPLEMENTARITY DETERMINATION REGIONS.
ES2592271T3 (en) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Polypeptide production methods by regulating the association of polypeptides
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
DK1999154T3 (en) 2006-03-24 2012-12-03 Merck Patent Gmbh MANUFACTURED HETERODIMERED PROTEIN DOMAINS
RU2008142359A (en) 2006-03-28 2010-05-10 Ф.Хоффманн-Ля Рош Аг (Ch) COMPOSITION OF HUMAN MONOCLONAL ANTIBODY TO IGF-1R
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
US20080112961A1 (en) 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP2099823B2 (en) 2006-12-01 2022-02-09 Seagen Inc. Variant target binding agents and uses thereof
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
EP2155789B1 (en) 2007-05-01 2013-07-24 Research Development Foundation Immunoglobulin fc libraries
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
EP2208066A2 (en) 2007-10-03 2010-07-21 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009126304A1 (en) 2008-04-11 2009-10-15 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP3524620A1 (en) * 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
US8163509B2 (en) 2008-10-20 2012-04-24 The Regents Of The University Of Colorado, A Body Corporate Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
JP2012519170A (en) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー INSITU method for monitoring EMT status of tumor cells in vivo
WO2010112193A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
CA2757531A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
ES2537100T3 (en) 2009-04-07 2015-06-02 Roche Glycart Ag Trivalent bispecific antibodies
BRPI1016204A2 (en) 2009-04-22 2016-04-19 Merck Patent Gmbh antibody fusion proteins with modified fcrn binding sites
CN102459346B (en) 2009-04-27 2016-10-26 昂考梅德药品有限公司 The method manufacturing heteromultimers molecule
WO2010136172A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
ES2548030T3 (en) 2009-06-01 2015-10-13 Medimmune, Llc Molecules with prolonged half-lives and uses thereof
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
SG177560A1 (en) 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP3112382A1 (en) 2009-12-29 2017-01-04 Emergent Product Development Seattle, LLC Heterodimer binding proteins and uses thereof
MX350983B (en) 2010-02-08 2017-09-27 Regeneron Pharma Common light chain mouse.
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
EA201201435A1 (en) 2010-04-20 2013-04-30 Генмаб А/С HETERODIMERNY ANTIBODY-Fc-CONTAINING PROTEINS AND METHODS FOR THEIR RECEIVING
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
MX352929B (en) 2010-11-05 2017-12-13 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain.
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
DK2698431T3 (en) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Maintenance of antigen-binding molecules in blood plasma and method of modifying immunogenicity
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. Antibody variants and uses thereof
KR101963923B1 (en) * 2011-08-23 2019-03-29 로슈 글리카트 아게 Bispecific t cell activating antigen binding molecules
CA2845147A1 (en) 2011-09-23 2013-03-28 Roche Glycart Ag Bispecific anti-egfr/anti igf-1r antibodies
LT2771364T (en) * 2011-10-27 2019-09-10 Genmab A/S Production of heterodimeric proteins
SI2794905T1 (en) 2011-12-20 2020-08-31 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
HUE053310T2 (en) 2012-03-16 2021-06-28 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents for generating the same
KR102171431B1 (en) 2012-04-20 2020-10-30 메뤼스 엔.페. Methods and means for the production of Ig-like molecules
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
WO2014009465A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
EP2890716A4 (en) 2012-08-31 2016-06-08 Univ North Carolina Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
AU2013322710A1 (en) 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
TWI653243B (en) 2013-04-29 2019-03-11 赫孚孟拉羅股份公司 Anti-IGF-1R antibody against FcRn binding and use thereof for treating vascular eye diseases
CN105164157B (en) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Modified asymmetric antibodies to FC-receptor binding and methods of use
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products

Also Published As

Publication number Publication date
MX2015015061A (en) 2016-02-11
HK1213578A1 (en) 2016-07-08
KR102282134B1 (en) 2021-07-27
US20210395355A1 (en) 2021-12-23
AU2019200635A1 (en) 2019-02-21
PH12015502470A1 (en) 2016-02-22
KR20210094669A (en) 2021-07-29
JP2022062120A (en) 2022-04-19
AU2020201429A1 (en) 2020-03-19
AU2019200635B2 (en) 2020-04-02
TWI747803B (en) 2021-12-01
AU2014261630A1 (en) 2015-09-17
CL2018002194A1 (en) 2018-11-23
PL2992012T3 (en) 2019-12-31
JP7426190B2 (en) 2024-02-01
US20160159894A1 (en) 2016-06-09
PE20190920A1 (en) 2019-06-26
WO2014177460A1 (en) 2014-11-06
PE20151807A1 (en) 2015-12-02
KR20160002858A (en) 2016-01-08
UA118029C2 (en) 2018-11-12
MY172430A (en) 2019-11-25
EP3628685A1 (en) 2020-04-01
MX365787B (en) 2019-06-14
IL241787B (en) 2021-04-29
CR20150512A (en) 2015-11-19
TW201446799A (en) 2014-12-16
ES2746136T3 (en) 2020-03-04
AU2014261630B2 (en) 2019-05-09
CA2904806A1 (en) 2014-11-06
CN105143262A (en) 2015-12-09
CA2904806C (en) 2021-11-23
EP2992012A1 (en) 2016-03-09
CL2018002193A1 (en) 2018-11-23
EA201501063A1 (en) 2016-05-31
AU2020201429B2 (en) 2022-06-16
JP2016528167A (en) 2016-09-15
CL2015003126A1 (en) 2016-06-03
EP2992012B1 (en) 2019-07-17
JP2018197264A (en) 2018-12-13
BR112015027385A2 (en) 2017-08-29
US11091541B2 (en) 2021-08-17
SG10201800492PA (en) 2018-03-28

Similar Documents

Publication Publication Date Title
HUS2200041I1 (en) Anti-cd3 antibodies and methods of use
IL241787B (en) Human fcrn-binding modified antibodies and methods of use
IL280155A (en) Anti-siglec-8 antibodies and methods of use thereof
IL290547A (en) Antibodies and methods of use
IL244495B (en) Anti-alpha-synuclein antibodies and methods of use
HK1225612A1 (en) Anti-ly6e antibodies and methods of use